Xenon Pharmaceuticals Inc. buy melinda
Startpreis
19.11.18
/
50%
7,62 €
Kursziel
17.12.18
9,56 €
Rendite (%)
-23,55 %
Endpreis
17.12.18
5,83 €
Zusammenfassung
Diese Einschätzung wurde am 17.12.18 mit einem Endkurs von 5,83 € beendet. Abwärts ging es seit Start der Einschätzung mit Xenon Pharmaceuticals Inc.. Verglichen mit dem Start ergibt sich eine Rendite von -23,55 %. melinda hat 50% Zuversicht bei dieser EinschätzungRendite ohne Dividenden (%)
| Name | 1W | 1M | 1J | 3J |
|---|---|---|---|---|
| Xenon Pharmaceuticals Inc. | -6,06 % | -6,06 % | -3,13 % | - |
| iShares Core DAX® | -0,05 % | 4,83 % | 17,06 % | 18,81 % |
| iShares Nasdaq 100 | 1,66 % | 2,42 % | 38,70 % | 56,56 % |
| iShares Nikkei 225® | 0,66 % | -2,17 % | 13,16 % | 7,77 % |
| iShares S&P 500 | 0,96 % | 2,55 % | 30,49 % | 47,35 % |
Kommentare von melinda zu dieser Einschätzung
In der Diskussion Xenon Pharmaceuticals Inc. diskutieren
SecteurRecherche biotechnologique et médicale Agenda 30/11 Présentation
Provides drug discovery and development services
Xenon Pharmaceuticals, Inc. is a biopharmaceutical company.
It engages in discovering and developing a pipeline of differentiated therapeutics.
It has built a core enabling discovery platform for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies.
The company has an integrated platform that includes in-house capabilities for human genetics, small molecule drug discovery and preclinical and clinical development.
Xenon Pharmaceuticals was founded by Simon Neil Pimstone, John J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.
Xenon Pharmaceuticals, Inc. is a biopharmaceutical company.
It engages in discovering and developing a pipeline of differentiated therapeutics.
It has built a core enabling discovery platform for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies.
The company has an integrated platform that includes in-house capabilities for human genetics, small molecule drug discovery and preclinical and clinical development.
Xenon Pharmaceuticals was founded by Simon Neil Pimstone, John J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.
Nombre d'employés : 81 personnes.
(Vom Mitglied beendet)
Beendete Einschätzungen von melinda zu Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc.
Startkurs
Kursziel
Rendite (%)
2,66 €
25.09.17
25.09.17
5,68 €
05.02.18
05.02.18
8,47 %
05.02.18
05.02.18
Xenon Pharmaceuticals Inc.
Startkurs
Kursziel
Rendite (%)
2,95 €
25.09.17
25.09.17
6,30 €
05.02.18
05.02.18
8,47 %
05.02.18
05.02.18
Xenon Pharmaceuticals Inc.
Startkurs
Kursziel
Rendite (%)
4,24 €
25.03.17
25.03.17
8,12 €
25.09.17
25.09.17
-37,23 %
25.09.17
25.09.17